Contagion®

The Evolving Childhood Vaccine Schedule: Considerations for Those With Chronic Diseases, Immunocompromised | Contagion Live In this episode, the panel discusses the continued importance of getting all children vaccinated and the potential unintended consequences of less individuals getting immunized if the current trends c...

In this episode, the panel discusses the continued importance of getting all children vaccinated and the potential unintended clinical care consequences of less individuals getting immunized if the current trends continue.

www.contagionlive.com/view/the-evo...

Phage-Antibiotic Combinations: What We Know, What We Don’t, and Where the Field Must Go Next | Contagion Live Emerging preclinical, compassionate-use, and randomized trial data suggest phage–antibiotic combinations may benefit select patients with multidrug-resistant infections, yet critical gaps in standardi...

In the latest @sidpharm.bsky.social Bench to Bedside column, authors @aelghali.bsky.social and @danaholger.bsky.social discuss phage-antibiotic combinations that may benefit select patients with multidrug-resistant infections.

Fewer Infants in US Receiving Protection Against Hepatitis B Virus | Contagion Live Rate of HBV vaccination of newborns in the US has declined by over 10 percent in the last 2 years, reversing decades of increasing coverage.

Rate of HBV vaccination of newborns in the US has declined by over 10 percent in the last 2 years, reversing decades of increasing coverage. #hepatitis

Top Infectious Disease News Stories Week of March 1 - March 7 | Contagion Live This week, read about the latest measles numbers, a risk assessment and antibiotic treatment of GAS pharyngitis, an analysis of ceftolozane-tazobactam over aminoglycosides/polymyxins for resistant P a...

This week, read about the latest measles numbers, a risk assessment and antibiotic treatment of GAS pharyngitis, an analysis of ceftolozane-tazobactam over aminoglycosides/polymyxins for resistant P aeruginosa, and more.

Measles Update: March 6, 2026 | Contagion Live The latest CDC numbers show a 12.76% increase of measles cases from week-to-week. This is a slight decrease in the number of cases from last week where there was a 15.7% increase. The data also shows ...

#BREAKING The latest CDC numbers show a 12.76% increase of measles cases from week-to-week. This is a slight decrease in the number of cases from last week where there was a 15.7% increase. The data also shows outbreaks in 3 new states. #IDsky #Medsky

CDC: Too Few Older, At-Risk Adults Receive Antiviral for COVID-19 | Contagion Live Despite increased risk for severe outcomes, most older adults and those with comorbidities do not receive antiviral treatment for COVID-19.

Despite increased risk for severe outcomes, most older adults and those with comorbidities do not receive antiviral treatment for COVID-19. #IDsky #Medsky

The Evolving Childhood Vaccine Schedule: Where’s the Data? | Contagion Live Despite the absence of vaccine data to support making changes, the ACIP continues to alter the pediatric schedule that will see less children getting immunized against vaccine-preventable diseases.

Despite the absence of vaccine data to support making changes, the ACIP continues to alter the pediatric schedule that will see less children getting immunized against vaccine-preventable diseases. In our continuing roundtable, our panel weighs in on this topic. #IDsky #Medsky

Review of The Risk Assessment and Treatment of Group A Streptococcal (GAS) Pharyngitis | Contagion Live In 2025, the Infectious Disease Society of America (IDSA) published the first part of an update to the clinical practice guideline on the diagnosis and management of GAS pharyngitis. Here is an overvi...

In 2025, the @idsainfo.bsky.social published the first part of an update to the clinical practice guideline on the diagnosis and management of GAS pharyngitis. Here is an overview of the risk assessment and antibiotic treatment of GAS pharyngitis. #IDsky #Medsky

#ICYMI Check out our roundtable, Clinical Insights: Childhood Vaccine Schedule Changes. This series discusses the ACIP’s new recommendations around pediatric vaccines.

Watch the first 2 episodes here: www.contagionlive.com/roundtables/...

One2PrEP Takes HIV Prevention to Center Stage, Using Culture and Conversation to Break Stigma | Contagion Live By launching during the Super Bowl pregame and the Grammy Awards, Gilead’s One2PrEP campaign used music, mainstream media, and bold visibility to normalize conversations about HIV prevention and expan...

Gilead’s One2PrEP campaign uses music, mainstream media, and bold visibility to normalize conversations about HIV prevention and expand awareness of evolving PrEP options.
#IDsky #Medsky

The Evolving Childhood Vaccine Schedule: Identifying Significant Policy Shifts | Contagion Live As the US continues to undergo massive policy changes to the pediatric childhood vaccine schedule, clinicians and families are left uncertain on recommendations and guidance. Our roundtable looks to p...

As the US continues to undergo policy changes to the pediatric childhood vaccine schedule, clinicians and families are left uncertain on recommendations and guidance. Our roundtable looks to provide some insights and answer questions to some of the more pressing topics around this evolving issue.

EMA Recommends Authorization for Moderna’s Flu–COVID Combination Vaccine | Contagion Live Moderna has cleared a major regulatory milestone in Europe after the EMA’s CHMP recommended approval of mRNA-1083 (mCOMBRIAX), the world’s first combined influenza and COVID-19 vaccine for adults aged...

Moderna has cleared a major regulatory milestone in Europe after the EMA’s CHMP recommended approval of mRNA-1083 (mCOMBRIAX), the world’s first combined influenza and COVID-19 vaccine for adults aged 50 and older.

With Endemic Measles on the Horizon, a Future With Greater Morbidity, Mortality and Healthcare Costs Seem Inevitable | Contagion Live A new modeling analysis shows the potential increases in cases, hospitalizations, deaths, as well as the healthcare costs associated with declining vaccination rates. Patricia Stinchfield, RN, MS, CP...

A modeling analysis shows the potential increases in cases, hospitalizations, deaths, as well as the healthcare costs associated with declining vaccination rates. Patricia Stinchfield, RN, MS, CPNP, discusses the measles outbreaks, strategies to increase vaccination. @nfidvaccines.bsky.social

Analysis Favors Ceftolozane-Tazobactam Over Aminoglycosides-Polymyxins for Resistant P aeruginosa | Contagion Live Ceftolozane-tazobactam cure rate for multidrug-resistant Pseudomonas aeruginosa infections is higher than with aminoglycosides-polymyxins and comparable to ceftazidime-avibactam.

Ceftolozane-tazobactam cure rate for multidrug-resistant Pseudomonas aeruginosa infections is higher than with aminoglycosides-polymyxins and comparable to ceftazidime-avibactam. #IDsky #Medsky

Clinical Insights Around Treating Measles | Contagion Live Patricia A Stinchfield, RN, MS, CPNP, discusses her medical experience caring for patients with it, and what fellow clinicians and the general public should know about less-discussed details and poten...

Patricia Stinchfield, RN, MS, CPNP, discusses her medical experience caring for patients with #measles, and what fellow clinicians and the general public should know about less-discussed details and potential complications. @nfidvaccines.bsky.social

Measles Update: February 27, 2026 | Contagion Live The latest CDC numbers show a 15.7% increase of measles cases from week-to-week. This is another large jump in cases, especially from last week where there was a 7.8% increase. The data also shows fur...

#Breaking The latest CDC numbers show a 15.7% increase of measles cases from week-to-week. This is another large jump in cases, especially from last week where there was a 7.8% increase. The data also shows further outbreak spread across more states.

Bictegravir-Lenacapavir: Further Study Insights on the Investigative HIV Therapy | Contagion Live Eric Meissner, MD, PhD, discusses the takeaways of the ARTISTRY-2, phase 3 study, which compared bictegravir/emtricitabine/tenofovir alafenamide to bictegravir/lenacapavir in adults with HIV who were ...

Eric Meissner, MD PhD, discusses the takeaways of the ARTISTRY-2, phase 3 study, which compared bictegravir/emtricitabine/tenofovir alafenamide to bictegravir/lenacapavir in adults with HIV who were virologically suppressed. #CROI2026

Long-Acting Injectable VH-499 Shows Favorable Safety and PK Profile in Early Study | Contagion Live Phase 1 data show that the long-acting HIV-1 capsid inhibitor VH-499 is well tolerated as a single intramuscular or subcutaneous injection and demonstrates pharmacokinetics supportive of long-acting d...

Phase 1 data show that the long-acting HIV-1 capsid inhibitor VH-499 is well tolerated as a single intramuscular or subcutaneous injection and demonstrates pharmacokinetics supportive of long-acting dosing intervals. #CROI2026

www.contagionlive.com/view/long-ac...

Switching to Bictegravir-Lenacapavir Combination Maintains HIV Virologic Suppression in Complex Regimen Patients | Contagion Live Chloe Orkin, MD, MSc, discusses the takeaways of the ARTISTRY-1 phase 3 study, including its efficacy and safety profile and the potential benefits of a single-tablet regimen in this patient populatio...

Dr. Chloe Orkin discusses the takeaways of the ARTISTRY-1 phase 3 study, including its efficacy and safety profile and the potential benefits of a single-tablet regimen in this patient population. #CROI2026

www.contagionlive.com/view/switchi...

Antiviral Emerges as a Highly Potent, First-in-Class Candidate for Hepatitis E | Contagion Live New in vitro data presented at CROI show that Atea Pharmaceuticals’ oral nucleotide analog AT-587 demonstrates markedly superior potency against hepatitis E virus compared with existing off-label opti...

New in vitro data presented at CROI show that Atea Pharmaceuticals’ oral nucleotide analog AT-587 demonstrates markedly superior potency against hepatitis E virus compared with existing off-label options, supporting plans to advance the candidate into phase 1 clinical development in 2026. #CROI2026

Doravirine/Islatravir Combination Maintains Virologic Suppression Through 96 Weeks | Contagion Live Amy Colson, MD, MPH, discusses data from the MK8591A-052 trial which showed that switching to doravirine/islatravir maintained durable virologic suppression with efficacy and safety comparable to cont...

Amy Colson MD, MPH, discusses data from the MK8591A-052 trial which showed that switching to doravirine/islatravir maintained durable virologic suppression with efficacy and safety comparable to continuing bictegravir/emtricitabine/tenofovir alafenamide. #CROI2026

Switch to Dovato Linked to Lower Rates of Steatotic Liver Disease Vs Biktarvy at 96 Weeks | Contagion Live New 96-week sub-group data from the PASO DOBLE study show that adults with virologically suppressed HIV who switched to Dovato experienced significantly lower rates of steatotic liver disease than tho...

New 96-week sub-group data from the PASO DOBLE study show that adults with virologically suppressed HIV who switched to Dovato experienced significantly lower rates of steatotic liver disease than those who switched to Biktarvy, particularly among individuals with weight gain. #croi2026

Novel Single-Tablet Regimen Demonstrates Noninferiority to Standard HIV Therapy | Contagion Live In the phase 3 ARTISTRY-2 trial, switching virologically suppressed people with HIV from B/F/TAF to a once-daily bictegravir/lenacapavir single-tablet regimen maintained viral suppression through Week...

In the phase 3 ARTISTRY-2 trial, switching virologically suppressed people with HIV from B/F/TAF to a once-daily bictegravir/lenacapavir single-tablet regimen maintained viral suppression through Week 48 with comparable safety and tolerability. #CROI2026
www.contagionlive.com/view/novel-s...

Switching to Doravirine/Islatravir Maintains Viral Suppression Through 96 Weeks | Contagion Live In a phase 3 study of virologically suppressed adults with HIV, switching to once-daily doravirine/islatravir (DOR/ISL 100/0.25 mg) maintained high rates of viral suppression through 96 weeks, with no...

In a phase 3 study of virologically suppressed adults with HIV, switching to once-daily doravirine/islatravir (DOR/ISL 100/0.25 mg) maintained high rates of viral suppression through 96 weeks, with no emergent resistance and a favorable safety profile. #CROI2026
www.contagionlive.com/view/switchi...

Traws Pharma Reports Differentiated COVID-19 and Influenza Antiviral Progress | Contagion Live Traws Pharma announced positive phase 2 results showing its investigational COVID-19 antiviral ratutrelvir as a possible alternative to Paxlovid, including for ineligible patients, while advancing tiv...

Traws Pharma announced positive phase 2 results showing its investigational COVID-19 antiviral ratutrelvir as a possible alternative to Paxlovid, including for ineligible patients, while advancing tivoxavir marboxil as a once-monthly oral prophylactic for seasonal influenza.

Top Infectious Disease News Stories Week of February 15 - February 21 | Contagion Live This week, read about the changes to the pediatric vaccine schedule, RSV protection, the FDA reversing course on Moderna's influenza vaccine, and more.

This week, read about the changes to the pediatric vaccine schedule, RSV protection, the FDA reversing course on Moderna's influenza vaccine, and more.

www.contagionlive.com/view/top-inf...

Measles Update: February 20, 2026 | Contagion Live The latest CDC numbers show a nearly 7.5% increase of measles cases from week-to-week. While the number of new measles cases are down from the previous week, there are more states and outbreaks circul...

The latest CDC numbers show a 7.9% increase of measles cases from week-to-week. While the number of new measles cases are down from the previous week, there are more states and outbreaks circulating throughout the US. #IDtwitter #Medtwitter

www.contagionlive.com/view/measles...

Infectious Disease Regulatory Watch: January Highlights | Contagion Live In this month's column, we look at the recommendation changes made by the CDC to the pediatric vaccine schedule, as well as the American Academy of Pediatrics' response with its own vaccine schedule.

In this month's column, we look at the recommendation changes made by the CDC to the pediatric vaccine schedule, as well as the American Academy of Pediatrics' response with its own vaccine schedule. #IDsky #Medsky

Strong Second-Season RSV Protection Data for Monoclonal Antibody in High-Risk Young Children | Contagion Live New phase 3 data show that Merck’s clesrovimab (Enflonsia) maintained a favorable safety profile and supportive pharmacokinetics in high-risk children under 2 years of age during a second RSV season. ...

New phase 3 data show that Merck’s clesrovimab (Enflonsia) maintained a favorable safety profile and supportive pharmacokinetics in high-risk children under 2 years of age during a second RSV season. The company plans to file for expanded regulatory approval. #IDsky #Medsky

New Acting CDC Director Named | Contagion Live The federal agency is bringing over NIH Director Jayanta "Jay" Bhattacharya, MD, PhD, to fill the position.

The federal agency is bringing over NIH Director Jayanta "Jay" Bhattacharya, MD, PhD, to fill the position.